Effects of angiotensin type 1 receptor antagonists on Parkinson’s disease progression: An exploratory study in the PPMI database
| dc.contributor | Udovin, Lucas | |
| dc.contributor | Otero Losada, Matilde | |
| dc.contributor | Bordet, Sofia | |
| dc.contributor | Chevalier, Guenson | |
| dc.contributor | Quarracino, Cecilia | |
| dc.contributor | Perez Lloret, Santiago | |
| dc.creator | Capani, Francisco | |
| dc.date | 2021-08-20 | |
| dc.date.accessioned | 2025-07-11T23:45:46Z | |
| dc.description | Fil: Capani, Francisco. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. | |
| dc.description | We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson’s Progress Marker Initiative (PPMI) study database. Methods: We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the PPMI. We compared the proportion of patients starting on L-DOPA during the first year of follow-up, and the changes in MDS-UPDRS total score and sub-scores during the first five follow-up years for patients exposed or not to ARBs or ACEIs. Results: Treatment with ARBs did not affect the proportion of patients on L-DOPA during the first year (adjusted OR, 95% CI = 0.26, 0.03–2.18, N.S.) while reduced MDS-UPDRS total score (0.85, 0.76–0.95, p < 0.01). Patients treated with ACEIs experienced no changes in either measure. Conclusions: These results show potential signals for a beneficial effect with ARBs. Further clinical trials are warranted. | |
| dc.format | application/pdf | |
| dc.identifier | https://repositorio.barcelo.edu.ar/greenstone/collect/investig/index/assoc/HASH016f.dir/BRC_129_MED_BA.pdf | |
| dc.identifier | http://repositorio.barcelo.edu.ar/greenstone/collect/investig/index/assoc/HASH016f.dir/BRC_129_MED_BA.pdf | |
| dc.identifier.uri | https://dspace.barcelo.edu.ar/handle/123456789/107 | |
| dc.language | eng | |
| dc.publisher | Parkinsonism and Related Disorders 86 (2021) 34–37 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | ARTICULO | |
| dc.subject | MEDICINA | |
| dc.subject | ENFERMEDAD DE PARKINSON | |
| dc.title | Effects of angiotensin type 1 receptor antagonists on Parkinson’s disease progression: An exploratory study in the PPMI database | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Files
Original bundle
1 - 1 of 1